Journal
NEUROBIOLOGY OF AGING
Volume 35, Issue 6, Pages 1275-1285Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2013.12.031
Keywords
Alzheimer's disease; Amyloid beta peptide; The neurovascular unit; Pinocembrin; The receptor for advanced glycation end products
Categories
Funding
- National Natural Science Foundation of China [81102830]
- Peking Union Medical College Youth Fundamental Project [2012J20]
- Major Scientific and Technological Special Project for Significant New Drugs Creation [2013ZX09J13102-05C]
- Specialized Research Fund for the Doctoral Program of Higher Education [20111106120023]
- Beijing New-star Plan of Science and Technology [xx2013065]
Ask authors/readers for more resources
Amyloid-beta (A beta) peptides accumulate in the brain and initiate a cascade of pathologic events in Alzheimer's disease. The receptor for advanced glycation end products (RAGE) has been implicated to mediate A beta-induced perturbations in the neurovascular unit (NVU). We demonstrated that pinocembrin exhibits neuroprotection through inhibition of the A beta and/or RAGE pathway, but the therapeutic role and mechanism involved are not ascertained. Here, we report that a 3-month treatment with pinocembrin prevents the cognition decline in APP/PS1 transgenic mice without altering A beta burden and oxidative stress. Instead, pinocembrin is effective in conferring neurovascular protection through maintenance of neuropil ultrastructure, reduction of glial activation and levels of inflammatory mediators, preservation of microvascular function, improving the cholinergic system by conserving the ERK-CREB-BDNF pathway, and modulation of RAGE-mediated transduction. Furthermore, in an in vitro model, pinocembrin provides the NVU protection against fibrillar A beta(1-42), accompanied by regulation of neurovascular RAGE pathways. Our findings indicate that pinocembrin improves cognition, at least in part, attributable to the NVU protection, and highlights pinocembrin as a potential therapeutic strategy for the prevention and/or treatment of Alzheimer's disease. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available